Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-05-05 09:52 |
Pharming aankondiging publicatie resultaten eerste kwartaal 2022
|
Dutch | 177.5 KB | ||
| 2022-05-05 09:52 |
Pharming aankondiging publicatie resultaten eerste kwartaal 2022
|
Dutch | 156.3 KB | ||
| 2022-04-26 08:18 |
Pharming receives agreement of Paediatric Investigation Plan and Promising Inno…
|
English | 232.1 KB | ||
| 2022-04-22 08:14 |
Pharming announces change in its holding in BioConnection following a substanti…
|
English | 167.2 KB | ||
| 2022-04-07 08:41 |
Pharming announces the filing of its 2021 Annual Report, with Form 20-F also fi…
|
English | 148.2 KB | ||
| 2022-04-06 21:57 | English | 2.6 MB | |||
| 2022-03-28 08:13 |
Pharming Announces Presentation of Positive Results of Phase III Leniolisib Tri…
|
English | 146.1 KB | ||
| 2022-03-17 08:33 |
Pharming Group reports financial results for full year 2021
|
English | 68.3 KB | ||
| 2022-03-08 08:26 |
Pharming Group Notice of 2021 Full Year Results
|
English | 26.3 KB | ||
| 2022-02-02 08:47 |
Pharming announces positive results of Phase II/III pivotal clinical study of l…
|
English | 30.5 KB | ||
| 2022-01-06 08:34 |
Pharming receives positive EMA decision on paediatric investigation plan (PIP) …
|
English | 28.3 KB | ||
| 2021-12-23 08:21 |
Pharming Group and Sanofi renew strategic manufacturing partnership agreement
|
English | 32.5 KB | ||
| 2021-10-28 08:39 |
Pharming Group reports financial results for the first nine months of 2021
|
English | 58.3 KB | ||
| 2021-10-22 08:24 |
Pharming Group Notice of 9M Results
|
English | 134.4 KB | ||
| 2021-09-14 08:23 |
Pharming announces results from clinical trials for the treatment of COVID-19 w…
|
English | 145.8 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
